

Meds offer slight symptom relief in overactive bladder

May 20 2015



(HealthDay)—For women with overactive bladder, medications delivered as a daily dose correlate with small reductions in urge incontinence episodes and voiding, according to a review published online May 6 in *Obstetrics & Gynecology*.

W. Stuart Reynolds, M.D., M.P.H., from the Vanderbilt University Medical Center in Nashville, Tenn., and colleagues conducted a systematic review to summarize evidence about reduction in voiding and resolution of urine loss in overactive bladder, comparing data from the active drug arms with the placebo arms. Data were included from 50 randomized controlled trials (one good quality, 38 fair, 11 poor).

The researchers found that medications delivered as a daily dose reduced



urge incontinence by 1.73 episodes per day from 2.79 at baseline, and reduced voids by 2.06 per day from 11.28 at baseline. Placebo was associated with reductions of 1.06 for urge incontinence episodes and 1.2 for voids per day. There was no demonstration of superiority for one agent over another. Ninety-eight percent of the studies reporting funding were industry sponsored

"Evidence from more than 27,000 women participating in randomized controlled trials suggests that improvement in symptoms with anticholinergic management of <u>overactive bladder</u> is modest and rarely fully resolves symptoms," the authors write.

One author disclosed financial ties to Allergan in a study examining onobotulinum toxin bladder infections for the treatment of urge incontinence.

More information: <u>Full Text (subscription or payment may be required)</u>

Copyright © 2015 HealthDay. All rights reserved.

Citation: Meds offer slight symptom relief in overactive bladder (2015, May 20) retrieved 20 March 2024 from

https://medicalxpress.com/news/2015-05-meds-slight-symptom-relief-overactive.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.